Advances in Bispecific Antibodies for B-Cell Non-Hodgkin Lymphoma: Rapid Response From New Orleans

Non-Hodgkin lymphoma (NHL) is the most common type of lymphoma, of which B-cell lymphomas (eg, diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], and mantle cell lymphoma [MCL]) are some of the most common subtypes. Historically, first-line treatment is most commonly rituximab plus chemotherapy with or without radiation therapy. With treatment advances, more patients are eligible for newer first-line treatment options such as immunotherapy, targeted therapy, and CAR T-cell therapies. Despite these therapeutic advances, as many as half of the patients will relapse. To improve survival rates and clinical outcomes among patients with relapsed/refractory B-cell NHL, novel treatment approaches are under investigations, including bispecific antibodies (bsAbs), which have been shown to elicit deep and durable responses in these patients, including those with heavily pretreated diseases. In this educational activity, expert faculty in the field of NHL review recently presented data from studies evaluating bsAbs in B-cell NHL and the relevance of these findings to clinical practice.